These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38179696)

  • 1. Perioperative hemostasis management in patients with von Willebrand disease: an institutional experience.
    Toenges R; Miesbach W; Ludwig K; Krammer-Steiner B
    Blood Coagul Fibrinolysis; 2024 Mar; 35(2):49-55. PubMed ID: 38179696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
    Howman R; Barnes C; Curtin J; Price J; Robertson J; Russell S; Seldon M; Suppiah R; Teague L; Barrese G
    Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
    Borel-Derlon A; Federici AB; Roussel-Robert V; Goudemand J; Lee CA; Scharrer I; Rothschild C; Berntorp E; Henriet C; Tellier Z; Bridey F; Mannucci PM
    J Thromb Haemost; 2007 Jun; 5(6):1115-24. PubMed ID: 17403090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of von Willebrand disease.
    Rodeghiero F; Castaman G
    Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemostatic treatment in connection with surgery in patients with von Willebrand disease.
    Lethagen S
    Haemophilia; 1999 May; 5 Suppl 2():64-7. PubMed ID: 23401903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy and Safety of Fanhdi
    Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures.
    Desprez D; Drillaud N; Flaujac C; Volot F; Pan-Petesch B; Beurrier P; Cussac V; Feugeas O; Pailler Y; Callegarin A; Trossaërt M; de Raucourt E
    Haemophilia; 2021 Mar; 27(2):270-276. PubMed ID: 33550648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
    Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM;
    J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience.
    Khair K; Batty P; Riat R; Bowles L; Burgess C; Chen YH; Hart D; Platton S; Pasi J; Liesner R
    Haemophilia; 2015 Jan; 21(1):e44-50. PubMed ID: 25112927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
    Lissitchkov TJ; Buevich E; Kuliczkowski K; Stasyshyn O; Cerqueira MH; Klukowska A; Joch C; Seifert W
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):152-162. PubMed ID: 27203734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.